FDA Approves RYBREVANT FASPRO — Janssen Biotech, Inc.

# FDA Approves Janssen's RYBREVANT FASPRO Subcutaneous Formulation The FDA has approved Janssen Biotech's RYBREVANT FASPRO (amivantamab and hyaluronidase-lpuj), a subcutaneous formulation of the bispecific antibody amivantamab, potentially expanding market accessibility by offering patients and healthcare systems a more convenient administration option compared to intravenous delivery. The subcutaneous presentation could strengthen Janssen's competitive positioning in the non-small cell lung cancer market while potentially improving